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EXPANDED METHODS 
The AVIS-2 study was an observational multi-center study conceived in 2012 with the aim of creating a large 
database of individual adrenal vein sampling (AVS) studies performed worldwide. The original protocol was 
registered at clinicaltrials.gov (NCT01234220) and thereafter amended to reach the target recruitment number of 
1500 patients PA patients submitted to AVS in the last 15 years (2000-2015). 
Center selection criteria 
Eligible centers were identified from those that had published in English on primary aldosteronism (PA) and/or 
AVS in the last decade following the PICO strategy (P, population = adults with PA; I, intervention = AVS; C, 
comparator = simultaneous AVS vs. sequential catheterization technique, use of cosyntropin testing vs. non-
stimulated condition, use of bilaterally vs. unilaterally selective AVS results, use of absolute hormonal data vs. 
selectivity and lateralization indices; and O, outcome = the ways AVS was performed and interpreted, adrenal 
vein rupture) (24). Suitable studies were identified by computer-assisted database searches (PubMed database, 
U.S. National Library of Medicine) using the key words: aldosterone, primary aldosteronism (PA), endocrine 
hypertension, adrenal vein sampling, and the Boolean operator “AND”; scanning of reference lists; hand-
searching of relevant journals; correspondence with authors of relevant reports and meeting presentations; and 
consultation with experts in the field.  
All procedures were carried out according to the Helsinki Declaration. The protocol of the study was approved 
by the Ethics Committee of both the coordinating center and the participating centers. 
Inclusion/exclusion criteria 
After identification of the eligible centers the inclusion criteria were: a) age ≥ 18 years; b) center’s agreement to 
participate in the data collection; c) approval of the Ethics Committee. The only exclusion criteria were 
unwillingness of the lead investigator to participate in the study and/or lack of local Ethics Committee’s 
approval. 
Data collection and harmonization 
To warrant privacy protection data anonymization was systematically exploited in an ad hoc web-based 
platform (https://fm.dmcs.unipd.it) and a predefined form (reported below), which was created for on-line data 
collection. High quality of the data was ensured by using appropriate filters to prevent input of values that were 
not biologically plausible and/or were in wrong unit of measures. Data were securely stored in a protected server 
at the coordinating center, which had full access to the dataset; each local lead investigator had access with 
username and password to the his/her center’s database. 
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Data collection form for AVIS2 (1) 
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Data collection form for AVIS2 (2) 
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Data collection form for AVIS2 (3) 
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Summary List of the collected variables 
• Demography (sex 1 =M 2=F, weight, BMI, race, etc.); 
• AVS date (MM/DD/YYYY);  
• Birth date (MM/DD/YYYY);  
• Calculated age at AVS = AVS date (MM/DD/YYYY)- Birth date (MM/DD/YYYY) in years;  
• Systolic and diastolic blood pressure values (mmHg) at the time of AVS; 
• Ongoing medical therapy at the time of AVS; 
• Biochemical profile at baseline (sK+, plasma aldosterone concentration (PAC); plasma renin 
activity (PRA). 
• AVS protocol (bilaterally simultaneous/sequential; stimulated/unstimulated). 
• PAC and plasma cortisol concentration (PCC) in each adrenal vein and in the inferior vena cava 
blood; 
• Concordance/discordance between imaging and AVS results. 
• Treatment modality: right/left/bilateral laparoscopic adrenalectomy; medical treatment. 
• Blood pressure outcome at 6-months defined as reported in Supplemental Table 2. 
• Persistence /correction of hypokalemia at follow-up. 
• Serum K+, PAC and PRA at follow-up. 
• Complications: adrenal vein rupture. 
• Diagnosis (unilateral aldosterone-producing adenoma (APA); bilateral APA, unilateral adrenal 
hyperplasia; bilateral adrenal hyperplasia. 
The conclusive diagnosis of unilateral PA required demonstration of biochemical cure at follow-up. 
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Supplemental table 1: Pre-specified definitions of the BP outcome. The PASO criteria, which were 
proposed afterward based on expert consensus are also reported for comparison. 
 
   PASO 
CRITERIA* 
Cure normotension (BP < 140/90 mmHg) without any 
antihypertensive agents. 
Complete 
clinical 
success 
Improvement Marked normotension on the same or reduced number of medications 
and BP similar to baseline but with a marked decrease (> 2 
drugs) of medications. Partial 
clinical 
success Mild a fall of systolic and/or diastolic BP > 10%, but without 
achievement of normotension with the same or reduced 
therapy. 
No improvement no fall of systolic and/or diastolic BP and/or need for 
increased number and/or dose of antihypertensive 
medications. 
Absent 
clinical 
success 
 
BP = Blood Pressure; *PASO consensus from Williams TA, Lancet Diabetes Endocrinol 2017; 5(9):689-699, 
for comparison 
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Supplemental Table 2. Number of AVS included, technique, protocol and diagnostic criteria in use at participating centers.  
 
Center ID Number of AVS Years Technique Pharm. Stimulation Selectivity criteria Lateralisation criteria 
#14 6 2009-2011 Sequential Unstimulated SI unstim. > 3.0 LI unstim. > 4.0 
#18 9 2010-2015 Sequential Cos.  SI Cos. > 3.0 LI Cos. > 4.0 
#2 11 2007-2009 Bil. sim. Unstimulated SI unstim. > 2.0 LI unstim. > 2.0 
#19 15 2012-2015 Sequential Unstimulated SI unstim. > 3.0 LI unstim. > 2.0 
#4 17 2005-2012 Sequential Unstimulated SI unstim. > 1.36 LI unstim. > 3.0 
#7 27 2000-2009 Sequential Unstimulated /  Cos.  SI unstim. > 2.0 SI Cos. >3.0 
LI unstim. > 4.0 
LI Cos. > 4.0 
#1 39 2010-2015 Sequential Unstimulated /  Cos.  SI unstim. > 2.0 SI Cos. >3.0 
LI unstim. > 3.0 
LI Cos. > 4.0 
#5 39 2008-2012 Sequential Unstimulated SI unstim. > 2.0 LI unstim. > 3.0 
#13 45 2000-2010 Bil. sim. Unstimulated /  Cos.  SI unstim. > 1.36 SI Cos. > 5.0 
LI unstim. > 2.0 
LI Cos. > 2.0 
#15 63 2000-2011 Bil. sim. Unstimulated /  Cos.  SI Cos. > 5.0 LI Cos. > 2.0.6 
#3 79 2005-2011 Bil. sim. Unstimulated /  Cos.  SI unstim. > 3.0 SI Cos. > 3.0 
LI unstim. > 3.0 
LI Cos. > 3.0 
#12 98 2005-2015 Sequential Cos.  SI Cos. > 5.0 LI Cos. > 3.0.5.0 
#17 101 2004-2015 Sequential Cos.  SI Cos. > 5.0 LI Cos. > 4.0 
#9 107 2005-2011 Sequential Cos.  SI Cos. > 2.0 (< 2010) SI Cos. > 3.0 (> 2010) 
LI Cos. > 3.0 (< 2010) 
LI Cos. > 4.0 (> 2010) 
#6 115 2006-2014 Sequential Unstimulated /  Cos.  SI Cos. > 5.0 LI Cos. > 2.0.6 
#11 143 2000-2013 Sequential Unstimulated SI unstim. > 2.0 LI unstim. > 2.0 
#8 144 2008-2013 Sequential Unstimulated SI unstim. > 2.0 LI unstim. > 4.0 
#16 196 2000-2015 Bil. sim. Unstimulated / Cos.  SI unstim. > 2.0 LI unstim. > 2.0 
#10 371 2000-2015 Sequential (< 2009) Bil. sim. (> 2009) Unstimulated SI unstim. > 2.0 LI unstim. > 5.0 
 
Bil. Sim. = Bilateral simultaneous AVS; Cos. = Cosyntropin; LI= lateralization index; SI= selectivity index; 
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Supplemental Table 3: Baseline demographic, clinical and biochemical features of the 
1625 PA patients. 
 
Variable Value 
Age (years) 50.8 ± 10.8 
Sex (M/F), n (%) 985 (60.6)/ 640 (39.4) 
Ethnicity (%)  
Caucasians 75.2 
Asians 20.7 
Africans 3.6 
Hispanics 0.6 
Body Mass Index (Kg/m2) 28.4 ± 5.3 
Systolic BP (mmHg) 152 ± 20 
Diastolic BP (mmHg) 92 ± 13 
Heart rate (beats/min) 73 ± 12 
Anti-hypertensive treatment (n. of drugs) 2.26 (0-8) 
Serum K+ (mmol/L) 3.6 ± 0.5 
Hypokalemia (%) 41.4 
PRA (ng/mL/h) 0.30 (0.20 – 0.57) 
PAC (ng/dL) 24.8 (15.4 – 33.6) 
PAC (pmol/L, Système International) 688 (428 - 933) 
ARR (ng/dL)/(ng/mL/h) 65.5 (36.3 – 118.8) 
ARR (pmol/L/ng/mL/h, Système 
International) 
1818 (1008 - 3298) 
Imaging (Single node/bilateral nodes/normal 
adrenals, %; n = 1470) 
61.5/8.4/30.1 
 
Mean ± SD, or median and IQ range (PRA, PAC and ARR) or mean and range (n. of drugs). Abbreviations: 
PRA: plasma renin activity; PAC: plasma aldosterone concentration; ARR: aldosterone/renin ratio.
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Supplemental Table 4: Rate of selective AVS studies under unstimulated and cosyntropin-stimulated conditions 
 
SI  
cut-off 
Unstimulated 
(n=1274) 
p for comparison with the 
Cosyntropin-stimulated value 
p for comparison with the most used post-
Cosyntropin-stimulated value (SI ≥ 5.0) 
Cosyntropin  
(n=742) 
Right 
1.1 1129 (88.6%) ns 2 x 10-3 674 (90.8%) 
1.4 1056 (82.9%)* 4 x  10-3 ns 651 (87.7%)* 
2.0 951 (74.6%)* < 10-3 < 10-3 641 (86.4%)* 
3.0 779 (61.1%)* < 10-3 < 10-3 631 (85.0%)* 
4.0 692 (54.3%)* < 10-3 < 10-3 627 (84.5%) 
5.0 618 (48.5%)* < 10-3 < 10-3 621 (83.7%)* 
Left 
1.1 1228 (96.4%) 0.004 ns 735 (99.1%) 
1.4 1187 (93.2%)* < 0.001 ns 734 (98.9%) 
2.0 1057 (83.0%)* < 10-3 < 10-3 729 (98.2%)* 
3.0 876 (68.8%)* < 10-3 < 10-3 723 (97.4%)* 
4.0 774 (60.8%)* < 10-3 < 10-3 715 (96.4%)* 
5.0 698 (54.8%)* < 10-3 < 10-3 706 (95.1%)* 
Bilateral 
1.1 1099 (86.3%) 1 x 10-2 3 x 10-3 669 (90.2%) 
1.4 1007 (79.0%)* = 10-3 ns 646 (87.1%)* 
2.0 857 (67.3%)* < 10-3 < 10-3 636 (85.7%)* 
3.0 667 (52.4%)* < 10-3 < 10-3 624 (84.1%)* 
4.0 570 (44.7%)* < 10-3 < 10-3 615 (82.9%)* 
5.0 489 (38.4%)* < 10-3 < 10-3 603 (81.3%)* 
 
Number and rate of successful AVS studies by different selectivity index (SI) cutoffs.  
Grey shaded cells identify the cutoff values recommended by current guidelines/experts’ consensus; the other values are those identified in the AVIS-1 study. The SI value 
cutoff of 1.4 was identified in this study by the Youden index analysis (see text for explanation and Figure 3; SIunstimulated = 1.4). 
In each column * indicates that use of the higher cut-off implies a statistically significant fall of AVS studies judged to be successful at the p<0.05 alpha value, as compared 
to the immediately lower cutoff value.  
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Supplemental Table 5: Rate of selective unstimulated AVS studies performed with or without use of the intraprocedural rapid cortisol 
assay (IRCA) and comparison with Cosyntropin stimulation. 
 
SI 
cutoff 
Unstimulated 
no IRCA 
(n=1096) 
p for comparison with the 
Unstimulated IRCA 
Unstimulated 
IRCA 
(n=178) 
p for comparison with the 
Cosyntropin-stimulated value 
p for comparison with the 
most used post-Cosyntropin-
stimulated value  (SI ≥ 5.0) 
Cosyntropin- 
stimulated 
(C; n=742) 
Right 
1.1 962 (87.8%) 0.020 167 (93.8%) ns < 10-3 674 (90.8%) 
1.4 896 (81.8%) =8x10-3 160 (89.9%) ns =0.038 651 (87.7%)* 
2.0 798 (72.8%)* < 10-3 153 (86.0%)* ns ns 641 (86.4%)* 
3.0 647 (59.0%)* < 10-3 132 (74.2%)* 0.001 =3x10-3 631 (85.0%)* 
4.0 576 (52.6%)* =10-3 116 (65.2%)* < 0.001 < 10-3 627 (84.5%) 
5.0 516 (47.1%)* 0.012 102 (57.3%)* < 0.001 < 10-3 621 (83.7%)* 
Left 
1.1 1053 (96.1%) ns 175 (98.3%) ns ns 735 (99.1%) 
1.4 1015 (92.6%) =0.050 172 (96.6%) 0.026 ns 734 (98.9%) 
2.0 893 (81.5%)* < 10-3 164 (92.1%)* < 0.001 ns 729 (98.2%)* 
3.0 726 (66.2%)* < 10-3 150 (84.3%)* < 0.001 < 10-3 723 (97.4%)* 
4.0 639 (58.3%)* < 10-3 135 (75.8%)* < 0.001 < 10-3 715 (96.4%)* 
5.0 582 (53.1%)* =3x10-3 116 (65.2%)* < 0.001 < 10-3 706 (95.1%)* 
Bilateral 
1.1 935 (85.3%) =0.015 164 (92.1%) ns < 10-3 669 (90.2%) 
1.4 851 (77.6%) 2x10-3 156 (87.6%) ns =0.047 646 (87.1%)* 
2.0 713 (65.1%)* < 10-3 144 (80.9%)* ns ns 636 (85.7%)* 
3.0 549 (50.1%)* < 10-3 118 (66.3%)* < 0.001 < 10-3 624 (84.1%)* 
4.0 472 (43.1%)* =3x10-3 98 (55.1%)* < 0.001 < 10-3 615 (82.9%)* 
5.0 412 (37.6%)*  ns 77 (43.3%)* < 0.001 < 10-3 603 (81.3%)* 
 
Number and rate of successful AVS studies according to different selectivity index (SI) cutoff values. Cosyntropin data are shown for comparison. The grey shaded listed SI 
values are those recommended by current guidelines/consensus papers; the other are those identified in the AVIS-1 study. The SI value cutoff of 1.4 was identified in this 
study by the Youden index analysis (see text for explanation and Figure 3; SIunstimulated = 1.4). 
As in Supplemental Table 5, in each column * indicates that use of the higher cut-off implies a statistically significant fall of AVS studies judged to be successful at the 
p<0.05 alpha value as compared to the immediately lower cutoff value. 
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Supplemental Table 6: Criterion values and coordinates of the ROC curve of un-
stimulated SI in the identification of Selectivity of AVS. 
 
Criteri
on 
Sensi
tivity 
Speci
ficity 
+LR -LR +PV -PV 
≥0.29 100.0 0.00 1.00   90.5   
>0.29 99.86 0.00 1.00   90.5 0.0 
>0.41 99.86 1.35 1.01 0.10 90.6 50.0 
>0.44 99.72 2.70 1.02 0.10 90.7 50.0 
>0.61 99.72 12.16 1.14 0.023 91.5 81.8 
>0.63 99.43 12.16 1.13 0.047 91.5 69.2 
>0.65 99.43 13.51 1.15 0.042 91.6 71.4 
>0.66 99.29 13.51 1.15 0.052 91.6 66.7 
>0.7 99.15 14.86 1.16 0.057 91.7 64.7 
>0.72 99.01 14.86 1.16 0.067 91.7 61.1 
>0.74 99.01 17.57 1.20 0.056 92.0 65.0 
>0.76 98.87 17.57 1.20 0.065 92.0 61.9 
>0.78 98.87 18.92 1.22 0.060 92.1 63.6 
>0.82 98.30 18.92 1.21 0.090 92.0 53.8 
>0.84 98.30 24.32 1.30 0.070 92.5 60.0 
>0.85 98.16 25.68 1.32 0.072 92.6 59.4 
>0.86 98.02 25.68 1.32 0.077 92.6 57.6 
>0.87 98.02 27.03 1.34 0.073 92.8 58.8 
>0.89 97.73 27.03 1.34 0.084 92.7 55.6 
>0.93 97.45 28.38 1.36 0.090 92.8 53.8 
>0.94 97.31 28.38 1.36 0.095 92.8 52.5 
>1.02 97.31 43.24 1.71 0.062 94.2 62.7 
>1.03 96.88 44.59 1.75 0.070 94.3 60.0 
>1.04 96.88 45.95 1.79 0.068 94.5 60.7 
>1.06 96.74 45.95 1.79 0.071 94.5 59.6 
>1.07 96.46 47.30 1.83 0.075 94.6 58.3 
>1.1 96.46 52.70 2.04 0.067 95.1 60.9 
>1.15 95.75 52.70 2.02 0.081 95.1 56.5 
>1.16 95.47 54.05 2.08 0.084 95.2 55.6 
>1.17 95.47 56.76 2.21 0.080 95.5 56.8 
>1.21 95.04 56.76 2.20 0.087 95.4 54.5 
>1.23 94.76 58.11 2.26 0.090 95.6 53.8 
>1.25 94.76 59.46 2.34 0.088 95.7 54.3 
>1.38 92.21 59.46 2.27 0.13 95.6 44.4 
>1.39 92.21 60.81 2.35 0.13 95.7 45.0 
>1.4 92.07 62.16 2.43 0.13 95.9 45.1 
>1.62 88.39 62.16 2.34 0.19 95.7 35.9 
>1.63 88.39 63.51 2.42 0.18 95.9 36.4 
>1.69 86.83 63.51 2.38 0.21 95.8 33.6 
>1.7 86.69 64.86 2.47 0.21 95.9 33.8 
>1.92 81.16 64.86 2.31 0.29 95.7 26.5 
>1.94 81.16 66.22 2.40 0.28 95.8 26.9 
>2.26 72.66 66.22 2.15 0.41 95.4 20.2 
>2.28 72.52 67.57 2.24 0.41 95.5 20.5 
>2.34 71.67 67.57 2.21 0.42 95.5 20.0 
>2.35 71.67 68.92 2.31 0.41 95.7 20.3 
>2.71 65.72 68.92 2.11 0.50 95.3 17.4 
>2.72 65.58 70.27 2.21 0.49 95.5 17.6 
>2.75 65.01 70.27 2.19 0.50 95.4 17.4 
Criteri
on 
Sensi
tivity 
Speci
ficity 
+LR -LR +PV -PV 
>2.76 64.87 71.62 2.29 0.49 95.6 17.6 
>2.96 61.05 71.62 2.15 0.54 95.4 16.2 
>2.97 60.91 74.32 2.37 0.53 95.8 16.6 
>3.02 60.20 74.32 2.34 0.54 95.7 16.4 
>3.05 60.20 75.68 2.47 0.53 95.9 16.6 
>3.06 59.92 75.68 2.46 0.53 95.9 16.5 
>3.08 59.77 77.03 2.60 0.52 96.1 16.7 
>4.05 49.86 77.03 2.17 0.65 95.4 13.9 
>4.07 49.72 78.38 2.30 0.64 95.6 14.0 
>4.2 49.15 78.38 2.27 0.65 95.6 13.9 
>4.21 48.73 79.73 2.40 0.64 95.8 14.0 
>4.44 47.03 79.73 2.32 0.66 95.7 13.6 
>4.46 47.03 81.08 2.49 0.65 96.0 13.8 
>8.8 29.04 81.08 1.53 0.88 93.6 10.7 
>8.87 29.04 82.43 1.65 0.86 94.0 10.9 
>9.39 28.19 82.43 1.60 0.87 93.9 10.7 
>9.51 28.19 83.78 1.74 0.86 94.3 10.9 
>11.7 23.94 83.78 1.48 0.91 93.4 10.4 
>11.8 23.94 85.14 1.61 0.89 93.9 10.5 
>12.41 22.95 85.14 1.54 0.91 93.6 10.4 
>12.49 22.95 86.49 1.70 0.89 94.2 10.5 
>12.91 22.24 86.49 1.65 0.90 94.0 10.4 
>12.98 22.10 87.84 1.82 0.89 94.5 10.6 
>17.14 16.01 87.84 1.32 0.96 92.6 9.9 
>17.34 16.01 89.19 1.48 0.94 93.4 10.0 
>20.21 13.31 89.19 1.23 0.97 92.2 9.7 
>20.45 13.31 90.54 1.41 0.96 93.1 9.9 
>30.66 6.94 90.54 0.73 1.03 87.5 9.3 
>30.9 6.94 91.89 0.86 1.01 89.1 9.4 
>32.61 6.37 91.89 0.79 1.02 88.2 9.3 
>32.67 6.37 93.24 0.94 1.00 90.0 9.5 
>35.3 5.81 93.24 0.86 1.01 89.1 9.4 
>35.6 5.81 94.59 1.07 1.00 91.1 9.5 
>36.78 5.24 94.59 0.97 1.00 90.2 9.5 
>37.28 5.24 95.95 1.29 0.99 92.5 9.6 
>42.83 3.82 95.95 0.94 1.00 90.0 9.5 
>44.14 3.82 97.30 1.42 0.99 93.1 9.6 
>62.17 1.13 97.30 0.42 1.02 80.0 9.4 
>66.33 1.13 98.65 0.84 1.00 88.9 9.5 
>75.14 0.85 98.65 0.63 1.01 85.7 9.4 
>75.54 0.85 100.0   0.99 100 9.6 
>397.9
7 
0.00 100.0   1.00   9.5 
	
Abbreviations: +LR = positive likelihood ratio; -
LR = negative likelihood ratio; +PV = positive 
predictive value; -PV = negative predictive value. 	
	
15	
	
Supplemental Table 7: Rates of identified unilateral PA (Lat. PA) and of unilateral adrenalectomy (Adx) in AVIS-2 by use of 
different combinations of cutoff values for the Selectivity Index (SI) and the Lateralization Index (LI) under unstimulated and  
cosyntropin-stimulated conditions. 
 
 Unstimulated (U)  
(n=1004) 
Cosyntropin (C) 
 (n=637) 
SI ≥ 1.4 p value  vs 2.0 SI ≥ 2.0 
p value  
vs 3.0 SI ≥ 3.0 
p value 
 vs 1.4 SI ≥ 5.0 
p value vs  
SIB ≥ 1.4 
LIB ≥ 2.0 
p value vs  
SIB ≥ 1.4 
LIB ≥ 3.0 
p value vs  
SIB ≥ 2.0 
LIB ≥ 2.0 
LI ≥ 2.0 
Lat. PA 558 (55.6%) 
< 10-3 
 
475 
(47.3%) 
< 10-3 
 
372 
(37.1%) 
< 10-3 
 
- - - - 
Unil. Adrx 398 (39.6%) 
< 10-3 
 
335 
(33.4%) 
< 10-3 
 
268 
(26.7%) 
< 10-3 
 
- - - - 
LI ≥ 3.0 
Lat. PA 468 (46.6%)* 
< 10-3 
 
400 
(39.8%)* 
< 10-3 
 
315 
(31.4%)* 
< 10-3 
 
269 
(42.2%) 
< 10-3 
 
ns ns 
Unil. Adrx 366 (36.5%)* 
< 10-3 
 
312 
(31.1%)* 
< 10-3 
 
248 
(24.7%)* 
< 10-3 
 
226 
(35.5%) ns ns ns 
LI ≥ 4.0 
Lat. PA 407 (40.5%)* 
< 10-3 
 
345 
(34.4%)* 
< 10-3 
 
269 
(26.8%)* 
< 10-3 
 
233 
(36.6%)* 
< 10-3 
 
< 10-3 
 
ns 
Unil. Adrx 340 (33.9%)* 
< 10-3 
 
289 
(28.8%)* 
< 10-3 
 
229 
(22.8%)* 
< 10-3 
 
208 
(32.7%)* 0.005 ns ns 
LI ≥ 5.0 
Lat. PA 365 (36.4)* 
< 10-3 
 
307 
(30.6%)* 
< 10-3 
 
242 
(24.1%)* 
< 10-3 
 
207 
(32.5%)* 
< 10-3 
 
< 10-3 
 
2 x 10-3 
 
Unil. Adrx 309 (30.8%)* 
< 10-3 
 
260 
(25.9%)* 
< 10-3 
 
209 
(20.8%)* 
< 10-3 
 
186 
(29.2%)* 
< 10-3 
 
2 x 10-3 
 
ns 
 
* = lower than previous cut-off, per column (McNemar test). 
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Supplemental Table 8: Results of a sensitivity analysis performed by excluding stepwise the contribution of each of the centers 
that furnished pairwise unstimulated and cosyntropin-stimulated AVS results.  
The pairwise comparison of the Lateralization Index (LI) values in the sub-cohort of patients with bilaterally selective AVS on both 
unstimulated and post-cosyntropin conditions showed consistently lower post-cosyntropin LI values even after exclusion of each 
center. 
  
 Whole cohort Unilateral PA 
   Lateralization Index  Unstimulated Post- cosyntropin p Unstimulated 
Post- 
cosyntropin p 
Excluded center#1 3.81 (1.71-19.61) 2.43 (1.40-11.45) < 10
-3 
 
17.01 (3.86-32.99) 9.96 (3.36-20.02) 0.003 
Excluded center#3 3.88 (1.97-21.64) 2.38 (1.37-9.60) 
< 10-3 
 21.07 (3.74-43.92) 7.07 (3.10-19.63) 
< 10-3 
 
Excluded center#6 3.89 (1.60-21.08) 2.70 (1.42-14.02) 
10-3 
 19.17 (5.33-40.02) 10.19 (3.47-24.5) 
 10-3 
 
Excluded center#13 3.91 (1.98-20.60) 2.97 (1.42-13.33) 
< 10-3 
 13.98 (3.817-30.18) 10.19 (3.15-20.55) 
3 x 10-3 
 
Excluded center#15 3.79 (1.61-20.35) 2.41 (1.37-9.59) < 10
-3 18.42 (3.86-33.86) 9.96 (3.36-20.02) < 10-3 
Excluded center#16 3.67 (1.66-18.47) 2.38 (1.37-9.69) < 10
-3 16.19 (4.27-30.18) 9.43 (3.52-18.44) 0.042 
 
Data presented as median (interquartile range).  
Successful AVS studies were defined as an SI ≥ 2.0 and ≥ 5.0 under unstimulated and post-cosyntropin conditions. 
Wilcoxon test was used to assess statistical significance. 
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Supplemental Table 9: Lateralization, adrenalectomy and blood pressure outcomes according to different sets of diagnostic 
criteria.   
 
 Unstimulated  
(n=880) Χ
2 for 
unstimulated 
(p) 
Cosyntropin 
 (n=580) Χ2 for all 
(p) Sets of criteria  SI ≥ 1.4 LI ≥ 2.0 
SI ≥ 2.0 
LI ≥ 2.0 
SI ≥ 2.0 
LI ≥ 3.0 
SI ≥ 3.0 
LI ≥ 2.0 
SI ≥ 3.0 
LI ≥ 3.0 
SI ≥ 5.0 
LI ≥ 3.0 
SI ≥ 5.0 
LI ≥ 4.0 
Bilaterally selective 
(% of total) 
724 
(82.3%) 
619 
(70.3%) 
619 
(70.3%) 
482 
(54.8%) 
482 
(54.8%) 
  
< 0.001 
478 
(82.4%) 
478 
(82.4%) 
  
< 0.001 
Unilateral PA (by AVS criteria) 
(% of total) 
508 
(57.7%) 
437 
(49.7%) 
369 
(41.9%) 
340 
(38.6%) 
289 
(32.8%) 
 
< 0.001 
246 
(42.4%) 
214 
(36.9%) 
 
< 0.001 
Adrenalectomized pts (meeting criteria) 
(% of total) 
(% of successful AVS) 
(% of unilateral PA) 
367 
(41.7%) 
(50.7%) 
(72.2%) 
311 
(35.3%) 
(50.2%) 
(71.2%) 
289 
(32.8%) 
(46.7%) 
(78.3%) 
246 
(28.0%) 
(51.0%) 
(72.4%) 
227 
(25.8%) 
(47.1%) 
(78.5%) 
 
< 0.001 
0.409 
0.044* 
206 
(35.5%) 
(43.1%) 
(83.7%) 
189 
(32.6%) 
(39.5%) 
(88.3%) 
 
< 0.001 
< 0.001 
< 0.001* 
Cure 
(% of total – Figure 4 top) 
(% of adrenalectomized pts – Figure 4 bottom) 
156 
(17.7%) 
(42.5%) 
135 
(15.3%) 
(43.4%) 
125 
(14.2%) 
(43.3%) 
104 
(11.8%) 
(42.3%) 
95 
(10.8%) 
(41.9%) 
 
< 0.001 
0.9957 
84 
(14.5%) 
(40.8%) 
75 
(12.9%) 
(39.7%) 
 
< 0.001 
0.9854 
Improvement 
(% of total – Figure 4 top) 
(% of adrenalectomized pts – Figure 4 bottom) 
194 
(22.0%) 
(52.9%) 
160 
(18.2%) 
(51.4%) 
148 
(16.8%) 
(51.2%) 
129 
(14.7%) 
(52.4%) 
119 
(13.5%) 
(52.4%) 
 
< 0.001 
0.993 
112 
(19.3%) 
(54.4%) 
106 
(18.3%) 
(56.1%) 
 
< 0.001 
0.955 
Marked 
(% of total) 
(% of adrenalectomized pts) 
139 
(15.8%) 
(37.9%) 
113 
(12.8%) 
(36.3%) 
105 
(11.9%) 
(36.3%) 
93 
(10.6%) 
(37.8%) 
87  
(9.9%) 
(38.3%) 
 
0.002  
0.981 
95  
(16.4%) 
(46.1%) 
91 
(15.7%) 
(48.1%) 
 
< 0.001 
0.042 
Mild 
(% of total) 
(% of adrenalectomized pts) 
55 
(6.3%) 
(15.0%) 
47 
(5.3%) 
(15.1%) 
43  
(4.9%) 
(14.9%) 
36  
(4.1%) 
(14.6%) 
32  
(3.6%) 
(14.1%) 
 
0.087 
0.998 
17  
(2.9%) 
(8.3%) 
15  
(2.6%) 
(7.9%) 
 
0.005 
0.059 
No Improvement 
(% of total – Figure 4 top) 
(% of adrenalectomized pts – Figure 4 bottom) 
17  
(1.9%) 
(4.6%) 
16  
(1.8%) 
(5.1%) 
16  
(1.8%) 
(5.5%) 
13  
(1.5%) 
(5.3%) 
13  
(1.5%) 
(5.7%) 
 
0.917 
0.979 
10  
(1.7%) 
(4.9%) 
8  
(1.4%) 
(4.2%) 
 
0.971 
0.992 
Data from patients with available follow up information (n = 880/1004 for unstimulated AVS and n = 580/637 for cosyntropin-stimulated AVS). * these suggest 
the higher confidence of physicians in recommending adrenalectomy based on more restrictive criteria or based on cosyntropin use.   
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Supplemental Table 10: Number and rate of PA patients submitted to adrenalectomy based on evidence of lateralization under 
unstimulated conditions, who had post-cosyntropin AVS results indicating bilateral disease.   
 
 
Diagnostic criterion 
Cosyntropin-stimulated 
SI ≥ 5.0 and LI ≥ 3.0 SI ≥ 5.0 and LI ≥ 4.0 
U
ns
tim
ul
at
ed
 
SI
 ≥
 1
.4
 LI ≥ 2.0 Adrenalectomy /Lateralization (n, %) 17/74 (23%) 27/86 (31%) 
LI ≥ 3.0 Adrenalectomy /Lateralization (n, %) 11/43 (26%) 20/53 (38%) 
LI ≥ 4.0 Adrenalectomy /Lateralization (n, %) - 16/38 (42%) 
SI
 ≥
 2
.0
 LI ≥ 2.0 Adrenalectomy /Lateralization (n, %) 14/65 (22%) 22/75 (29%) 
LI ≥ 3.0 Adrenalectomy /Lateralization (n, %) 11/39  (28%) 18/47 (38%) 
LI ≥ 4.0 Adrenalectomy /Lateralization (n, %) - 14/32 (44%) 
SI
 ≥
 3
.0
 LI ≥ 2.0 Adrenalectomy /Lateralization (n, %) 9/42 (21%) 15/48 (31%) 
LI ≥ 3.0 Adrenalectomy /Lateralization (n, %) 7/25 (28%) 12/30 (40%) 
LI ≥ 4.0 Adrenalectomy /Lateralization (n, %) - 9/19 (47%) 
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Supplemental figure 1.  
 
Rate of bilateral selectivity at different SI cutoff values on unstimulated conditions (n = 1274) and after 
cosyntropin- (n = 742) or metoclopramide- (n = 123) stimulation. 
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Supplemental figure 2.  
 
Frequency distribution of SI before and after cosyntropin stimulation. 
 
Both left and right SI values are plotted. Grey bars: Unstimulated AVS; Black bars: cosyntropin-stimulated. n = 402. X axis: Log(10) scale.		 	
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Supplemental figure 3.  
 
Rate of lateralization rate by different diagnostic values (whole cohort).  
 
 
 
Lateralization rates in the whole cohort (regardless of availability of data on surgical indication and performance) according to protocol (Unstimulated [n= 1274] vs 
cosyntropin stimulated [n = 742]), SI cut-off values (1.4, 2.0 and 3.0) and LI cut-off values (2.0-5.0) are shown on top of the bars. Dashed bars = rates of bilateral 
selectivity, by group, for comparison with lateralization and adrenalectomy rates.		
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Supplemental figure 4.  
 
Impact of cosyntropin and metoclopramide stimulation on AVS diagnostic indexes.  
 
Paired analysis within subgroups of AVS performed on both unstimulated and cosyntropin- (n = 402; left 
panels) or metoclopramide- (n = 123; right panels) stimulated conditions. RASI and LI shown for cases with 
unilateral PA confirmed at follow-up. White bars = unstimulated; grey bars = stimulated. COSYN = 
cosyntropin, METO = metoclopramide. Median, IQR. * = p < 0.0 
